Biontech vaccine protects against asymptomatic infections and B.1.1.7


A recent study published in the Lancet shows that BioNTech/Pfizer’s vaccine not only protects against severe COVID-19 but also protects against asymptomatic infections. This protective effect is 97.0%. This is the result of a survey of data on the effectiveness of vaccination in Israel, in which all people who tested positive were asked about symptoms. Vaccination reduced hospitalizations by 97.2%. The number of severe and critical cases decreased by 97.5% and the number of deaths by 96.7%. This was true for all age groups studied. People over 85 years of age were also 94.1% protected from infection, 96.9% protected from hospitalization, and 97.0% protected from death. An initial protective effect was already detectable 14 days after the first dose, but was still relatively weak at 58%. Maximum efficacy was achieved 7 days after the second dose. Two doses of BNT162b2 are highly effective in preventing symptomatic and asymptomatic SARS-CoV-2 infection in all age groups (≥16 years, including older adults ≥85 years). This also applies to COVID-19-related hospitalisations, severe illnesses, and deaths, including those caused by the B.1.1.7 SARS-CoV-2 variant.